Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
(See below!) Consensus report on safe use of GLP-1 medications in T1D Despite the fact that GLP-1 receptor agonists (and dual GLP-1/GIP receptor agonists) are not FDA-approved for use in T1D for any indication, people with T1D are still able to access these drugs since they are approved to treat obesity and overweight
CagriSema: This Novo Nordisk combination is a fixed-dose co-formulation of the GLP-1 agonist semaglutide and the long-acting amylin analogue cagrilintide
At the class level, both have a GI-dominant profile (nausea, vomiting, diarrhoea) that concentrates at dose escalation
Additionally, GLP-1 drugs, through their influence on hormonal regulation, might indirectly impact the delicate hormonal balance within the body
Increasing attention has been directed toward the concept of a therapeutic window of opportunity, which frames early PsA as a transitional phase characterized by musculoskeletal symptoms such as arthralgia, dactylitis, and subclinical enthesitis in patients with PsO, often preceding clinically evident arthritis (12)
It also means cagrilintide could potentially be an option for people who dont respond well to GLP-1-based medications, or who experience side effects that make GLP-1 drugs hard to tolerate
US$ 21.71
US$ 20.68
US$ 20.06
US$ 25.02
US$ 28.44
